CAR T-cell therapy bb2121 shows sustained promise for multiple myeloma – Healio
Healio |
CAR T-cell therapy bb2121 shows sustained promise for multiple myeloma
Healio CHICAGO — Chimeric antigen receptor T–cell therapy bb2121 demonstrated continued efficacy and safety among patients with relapsed or refractory multiple myeloma, according to data from a two-part, ongoing, phase 1 trial presented at the ASCO Annual … Bluebird Bio's "Impressive" Killer T-Cells Battle Myeloma, But Are … ASCO18: Positive readout marks step forward for Bluebird's CAR–T Promising Early Phase Results With bb2121 CAR T Treatment in Relapsed Refractory Multiple Myeloma |
